Prostaglandins in therapy of cardiovascular disease.
Szczeklik
A
A
Gryglewski
R J
RJ
D000527:Alprostadil; D000787:Angina Pectoris / Q000188:drug therapy; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000009:adverse effects / Q000627:therapeutic use*; D005112:Extracorporeal Circulation; D005342:Fibrinolysis / Q000187:drug effects; D006261:Headache / Q000139:chemically induced; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011458:Prostaglandins E / Q000627:therapeutic use; D011928:Raynaud Disease / Q000188:drug therapy; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D014664:Vasodilation / Q000187:drug effects
D011458:Prostaglandins E; D011464:Epoprostenol; D000527:Alprostadil